S
Sulaiman Ali Alharbi
Researcher at King Saud University
Publications - 334
Citations - 5877
Sulaiman Ali Alharbi is an academic researcher from King Saud University. The author has contributed to research in topics: Chemistry & Biology. The author has an hindex of 28, co-authored 239 publications receiving 3037 citations.
Papers
More filters
Journal ArticleDOI
The Multifaceted Role of Curcumin in Cancer Prevention and Treatment
Muthu K. Shanmugam,Grishma Rane,Madhu Mathi Kanchi,Frank Arfuso,Arunachalam Chinnathambi,M. E. Zayed,Sulaiman Ali Alharbi,Benny K. H. Tan,Alan Prem Kumar,Gautam Sethi,Gautam Sethi,Gautam Sethi +11 more
TL;DR: The current review focuses on the diverse molecular targets modulated by curcumin that contribute to its efficacy against various human cancers.
Journal ArticleDOI
In vitro antibacterial activity of ZnO and Nd doped ZnO nanoparticles against ESBL producing Escherichia coli and Klebsiella pneumoniae.
Abdulrahman Syedahamed Haja Hameed,Chandrasekaran Karthikeyan,Abdulazees Parveez Ahamed,Nooruddin Thajuddin,Nooruddin Thajuddin,Naiyf S. Alharbi,Sulaiman Ali Alharbi,Ganasan Ravi +7 more
TL;DR: The apoptotic nature of the cells was confirmed by the cell shrinkage, disorganization of cell wall and cell membrane and dead cell of the bacteria, and the antibacterial studies performed against extended spectrum β-lactamases producing strains of Escherichia coli and Klebsiella pneumoniae showed that the Nd doped ZnO NPs possessed a greater antibacterial effect.
Journal ArticleDOI
NF‑κB in cancer therapy
Feng Li,Jingwen Zhang,Frank Arfuso,Arunachalam Chinnathambi,M. E. Zayed,Sulaiman Ali Alharbi,Alan Prem Kumar,Kwang Seok Ahn,Gautam Sethi,Gautam Sethi,Gautam Sethi +10 more
TL;DR: The diverse molecular mechanism(s) by which the NF-κB pathway is constitutively activated in different types of human cancers, and the potential role of various oncogenic genes regulated by this transcription factor in cancer development and progression are highlighted.
Journal ArticleDOI
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
Xiaoyun Dai,Jingwen Zhang,Frank Arfuso,Arunachalam Chinnathambi,M. E. Zayed,Sulaiman Ali Alharbi,Alan Prem Kumar,Kwang Seok Ahn,Gautam Sethi +8 more
TL;DR: Both apoptotic and nonapoptotic pathways activated by TRAIL are summarized, as well as recent advances in developing TRAIL–receptor agonists for cancer therapy.
Journal ArticleDOI
Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer
Kanjoormana Aryan Manu,Muthu K. Shanmugam,Lalitha Ramachandran,Feng Li,Kodappully Sivaraman Siveen,Arunachalam Chinnathambi,M. E. Zayed,Sulaiman Ali Alharbi,Frank Arfuso,Alan Prem Kumar,Kwang Seok Ahn,Gautam Sethi,Gautam Sethi,Gautam Sethi +13 more
TL;DR: Results demonstrate that isorhamnetin can significantly enhance the anti-tumor effects of capecitabine through the negative regulation of NF-κB regulated oncogenic genes.